No Data
WAI YUEN TONG: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
Wai Yuen Tong Medicine Expects Higher Fiscal H1 Profit
Wai Yuen Tong Plans Board Meeting for Key Financial Decisions
Wai Yuen Tong (00897.HK) will hold a board of directors meeting on November 27 to approve the interim performance.
EWai Yuen Tong (00897.HK) announced that the board of directors will hold a meeting on November 27, 2024 (Wednesday) to consider and approve (including) the company and its subsidiaries' interim performance for the six months ended September 30, 2024, as well as consider the distribution of interim dividends (if any).
wai yuen tong (00897.HK) expects mid-term profit to be no less than 20 million Hong Kong dollars.
Gelonghui reported on November 15 that wai yuen tong (00897.HK) announced that the group anticipates recording a profit attributable to equity holders of approximately HKD 3,500,000 for the six months ending September 30, 2023 (including a loss attributable to equity holders of approximately HKD 8,900,000 from discontinued operations), increasing to not less than HKD 20,000,000 for the six months ending September 30, 2024. The increase in profit is mainly due to (i) fair value gains on investment properties, (ii) the reversal of impairment losses on properties, factories, and equipment, and (
Express News | Wai Yuen Tong Medicine - Expected Result Due to Fair Value Gains on Owned Investment Properties, Others
Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding
No Data
